PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL. - Wikidata - thesis-toulmin - TriplyDB

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

http://www.wikidata.org/entity/Q31122542

about

Calcium-Sensing Receptor Promotes Breast Cancer by Stimulating Intracrine Actions of Parathyroid Hormone-Related Protein.Parathyroid hormone-related protein overexpression protects goat mammary gland epithelial cells from calcium-sensing receptor activation-induced apoptosis.

P2860

Q41112230-C470AC3F-BF80-4ACC-BD73-31758F216489 Q42685679-DC4281FE-6F66-4B8C-87E3-CB9BE7769BAD

P2860

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

http://www.wikidata.org/entity/Q31122542

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@ast

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@en

type

label

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@ast

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@en

prefLabel

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@ast

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

@en

P1433

Q31122542-59E4ED9D-36C2-4EE9-9C6F-B94EF9AAB067

P1476

Q31122542-E9E4A4BA-154F-442E-8CFB-E1DFD59876F3

P2093

Q31122542-0C73E702-23CB-42A9-BE49-701912B731D8

Q31122542-DF82051C-1BE8-4C18-AF93-1192CD692F5D

P2860

Q31122542-041DAE21-A790-4386-838B-3C3618D364B1

Q31122542-08FFF242-3026-4D69-BA79-592D006DCCF5

Q31122542-0A3D20C2-1594-4C24-A147-E8A6056CE58C

Q31122542-0ECFB232-1F6B-4DA8-85B0-A557FB2D6832

Q31122542-116F73FF-9338-4D58-8924-D74F331B1868

Q31122542-11832ABF-40E9-4519-8DB8-603B54308690

Q31122542-171FC7CF-AE8A-4654-AD71-9C5E7543F76B

Q31122542-1A010F4F-31B9-47DA-A7C7-BE969758ACCD

Q31122542-23D219C2-C43D-4F4E-B9CE-AAD0CA13A49B

Q31122542-3633C36A-983C-4D4F-803F-BD6144F2FEA8

P304

Q31122542-883B3F94-E301-45A8-BE87-7B1802C3D25F

P31

Q31122542-743958E3-3247-48AA-BF1A-00B3CC04C297

P356

Q31122542-76C7B841-36B0-4EF2-A497-B549BFFAF49D

P407

Q31122542-047E0C35-F91C-421B-92E2-5D168592B7D6

P433

Q31122542-C17FA321-E4CC-42A1-8685-36590020112A

P478

Q31122542-2183810C-9970-4D62-A00F-CED2F7AF37F0

P50

Q31122542-4050104C-EF0F-46FF-8063-FCA89C10AC10

P577

Q31122542-9E6B0AA9-DAF1-4BC0-9098-EB9634F57D6A

P5875

Q31122542-2A13E92F-8169-4E37-8E53-CF5AF43C4102

P698

Q31122542-F96A21C0-4685-4CD2-86FE-4E9ECBCBFC0C

P921

Q31122542-B1D7B338-4B4F-4CF7-A450-E5B03A4C975C

P932

Q31122542-854CE980-699B-4754-9F71-262F68CBDE5C

P356

JOURNAL.PONE.0066343

P1433

P1476

PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL

@en

P2093

Steve Bouralexis

http://www.w3.org/2001/XMLSchema#string

Vanessa Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

The receptor for the cytotoxic ligand TRAIL

Identification and characterization of a new member of the TNF family that induces apoptosis

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide

Molecular dissection of the importin beta1-recognized nuclear targeting signal of parathyroid hormone-related protein

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development

A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression

Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

P304

e66343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0066343

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Matthew T Gillespie

P577

2013-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

245027516

http://www.w3.org/2001/XMLSchema#string

P698

23822995

http://www.w3.org/2001/XMLSchema#string

P921

P932

3688876

http://www.w3.org/2001/XMLSchema#string